Bionomics Limited to Participate in Upcoming November Investor Conferences

Rhea-AI Summary

Bionomics Limited (NASDAQ: BNOX) has announced its participation in two key investor conferences in November. The first is the Credit Suisse 31st Annual Healthcare Conference on November 10 at 8:35 am PT in Rancho Palos Verdes, CA, featuring a company presentation. The second event is the Evercore ISI 5th Annual HealthCONx Conference, which includes a fireside chat scheduled for November 29 at 9:15 am ET. Audio webcasts for these events will be available on Bionomics' website.

ADELAIDE, Australia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will participate in the following upcoming investor conferences in November:

• Credit Suisse 31^st Annual Healthcare Conference
  • Company Presentation: November 10^th at 8:35am PT in Rancho Palos Verdes, CA
     
• Evercore ISI 5^th Annual HealthCONx Conference
  • Fireside Chat: November 29^th at 9:15am ET

An audio webcast link for select events, when available, will be posted to Bionomics’ website in the Events and Presentations page of the Investors section.

Released on authority of the Executive Chairman.

FOR FURTHER INFORMATION PLEASE CONTACT:

General Ms Suzanne Irwin Company Secretary +61 8 8150 7400 CoSec@bionomics.com.au

Investor Relations Mr. Connor Bernstein Vice President, Strategy and Corporate Development +1 (650) 524-5143 cbernstein@bionomics.com.au

Investor Relations Kevin Gardner kgardner@lifesciadvisors.com

About Bionomics Limited

Bionomics (ASX:BNO, NASDAQ:BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious CNS disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.

www.bionomics.com.au

 

FAQ

What are the upcoming conferences for Bionomics Limited in November 2022?

Bionomics Limited will participate in the Credit Suisse 31st Annual Healthcare Conference on November 10 and the Evercore ISI 5th Annual HealthCONx Conference on November 29.

When is Bionomics presenting at the Credit Suisse Healthcare Conference?

Bionomics is scheduled to present at the Credit Suisse Healthcare Conference on November 10, 2022, at 8:35 am PT.

What is the date and time of Bionomics' fireside chat at the Evercore ISI Conference?

The fireside chat for Bionomics at the Evercore ISI 5th Annual HealthCONx Conference is set for November 29, 2022, at 9:15 am ET.

Where can I find the audio webcasts for Bionomics' conferences?

Audio webcasts for Bionomics' conferences will be posted on their website in the Events and Presentations section of the Investors page.

What is Bionomics Limited's focus in biopharmaceuticals?

Bionomics Limited focuses on developing novel allosteric ion channel modulators for serious central nervous system disorders.